CELL INTELLIGENCE · 肿瘤细胞治疗研究

探索长期疾病控制：Axicabtagene Ciloleucel CAR-T 细胞治疗或异基因造血细胞移植治疗复发/难治性大 B 细胞淋巴瘤

In Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relap

与 allo-HCT 相比，axi-cel 为 r/r LBCL 患者提供了更优的 PFS 和 OS，主要归因于治疗相关死亡率更低，以及在细胞治疗前对化疗难治性疾病患者的疾病控制得到改善。

通过确定的逻辑门 CAR 策略克服靶向 CD86 的 CAR-T 细胞的自相残杀

Overcoming fratricide of CD86 targeting CAR-T cells by defined logic-gate CAR strategy.

从 CAR-T 到 CAAR-T：通过独特型导向细胞治疗重新定义 B 细胞恶性肿瘤的靶向策略

From CAR-T to CAAR-T: redefining targeting strategies in B-cell malignancies through idiotype-directed cellular therapy.

靶向连接子序列的通用高灵敏度 CAR-T 细胞监测

Universal high-sensitivity CAR T-cell monitoring by targeting linker sequences.

整合跨膜 CD28 结构域后学术性 CAR-T ARI0002h 对正常和低表达 BCMA 骨髓瘤细胞增强的抗肿瘤活性

Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane

将 CD28-TMD 整合到 ARI0002h CAR 中可增强肿瘤控制，即使在靶抗原下调的复发模型中也是如此，从而提供更好的长期疾病管理。该修饰增强了对 BCMA 表达正常和降低的 MM 肿瘤细胞系的效力，表现出更优的代谢耐力和体内活性。

CAR-T 治疗的疗效、安全性和成本效果

Efficacy, safety and cost-effectiveness of CAR-T therapy.

靶向 CD19 CAR-T 细胞治疗的非 ICANS 神经毒性与运动及神经认知治疗中出现的不良事件：一例病例报告

Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case

肾脏病学趋势：从虚无主义到抗体介导排斥反应的靶向治疗

Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection.

m-EASIX（优于 EASIX）预测重度 CAR-T 细胞毒性、更差的总生存期，并区分细胞因子释放综合征与脓毒症

m-EASIX (better than EASIX) predicts severe CAR T-cell toxicities, worse overall survival, and discriminates cytokine release syndrome from sepsis.

m-EASIX 是一种实用且易于获取的工具，可用于早期预测严重的 CAR-T 细胞相关毒性、风险分层以及与脓毒症的鉴别诊断，有望指导临床决策和早期干预。

抗 CD19/22 与抗 BCMA 双靶向 CAR-T 细胞疗法用于一例多发性骨髓瘤合并继发性 B-ALL 患者

Dual anti-CD19/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL.